Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Arch Biopartners Inc V.ARCH

Alternate Symbol(s):  ACHFF

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is LSALT Peptide. The Company is engaged in the clinical development of LSALT Peptide and other DPEP-1 targeting drug candidates for indications where inflammation of the lungs, liver and kidneys is an unmet problem. LSALT Peptide is in a second phase II trial, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The Company has additional technology platforms in its portfolio, which are AB569 and Borg. AB569 is an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds.


TSXV:ARCH - Post by User

Post by Viking2233on Sep 09, 2023 3:38pm
363 Views
Post# 35627843

Buyers

BuyersWhere are the buyers? The stock is trading below 2018 yet we have achieved many positive milestones, reduced the risk.

We are now below $100 million market cap yet many similar staged companies have much higher market caps in the $Billions.

They all have institutional ownership where we have zero%, in my opinion that falls directly back on management. What are they doing and why can't they generate interest from institutional big boys?

We are long overdue for the 3rd party independent phase 2 peer review, no
idea when we will receive or if it will even have any positive impact on share price. I am sure the one analyst who covers ARCH is scratching his head.

The new phase 2 AKI trial should be starting soon, I hope we get an update from management.

I am disappointed with share price and lack of buying interest. It is obvious that CIBC and Scotia are shorting the stock for about 12 months now but the real issue is the lack of buying, low volume. If there was serious buying interest the share price would be much higher.

I believe management have backed themselves into a corner here with regards to attracting institutional buyers do to the fact our share price is below $10, we are on the TSX Venture exchange, our market cap is below $1B and the volume and liquidity are a big concern for the big boys.

I am confident we will see stellar data and results from the new phase 2 AKI trial but the shorting action and trading suggests the markets are signaling dilution/capital raise in the future for a future phase 3 trial.
<< Previous
Bullboard Posts
Next >>